From the beginning of the COVID-19 pandemic, the hunt for a vaccine has been at the front of all forecasts regarding when we will be able to resume some semblance of a normal life.
In concert with Germany-based BioNTech, a next-generation immunotherapy company pioneering novel therapies for infectious diseases, among other illnesses, premier biopharmaceutical company Pfizer has championed the development of multiple COVID-19 vaccine candidates in the hopes of finding a defense against the virus.
In a recent press release, both companies announced their plans to “jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites.” Combining BioNTech’s mRNA vaccine platforms with Pfizer’s expertise in research and development, as well as its global manufacturing and distribution network, the partners have seen early success with their candidates and are endeavoring to launch trials by the end of April 2020.
“Combating the COVID-19 pandemic will require unprecedented collaboration across the innovation ecosystem, with companies coming together to unite capabilities like never before," Pfizer’s Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, said in the same press release. "I am proud of Pfizer’s collaboration with BioNTech and have every confidence in our ability to harness the power of science – together – to bring forth a potential vaccine that the world needs as quickly as possible.” .
PTC is so grateful to Pfizer for their efforts during these challenging times.
To nominate a COVID-19 Hero, please reach out to Alexa Rice with details.